Low efficacy of nevirapine (HIVNET012) in preventing perinatal HIV-1 transmission in a real-life situation
- 1 September 2004
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 18 (13), 1854-1856
- https://doi.org/10.1097/00002030-200409030-00018
Abstract
Since 2001, the unrestricted use of HIVNET012 has been recommended for the prevention of mother-to-child transmission in low-resource settings, despite the lack of validated efficacy data outside research settings. We implemented the nevirapine regimen in a real-life situation in Kenya. The perinatal HIV-1 transmission rate at 14 weeks was 18.1%, similar to the 21.7% before the intervention. These data call for further evaluation of the simple nevirapine regimen in field conditions, and underline the need for alter-native strategies.Keywords
This publication has 5 references indexed in Scilit:
- Low Rate of Mother-to-Child Transmission of HIV-1 After Nevirapine Intervention in a Pilot Public Health Program in Yaound??, CameroonJAIDS Journal of Acquired Immune Deficiency Syndromes, 2003
- Timing of the maternal drug dose and risk of perinatal HIV transmission in the setting of intrapartum and neonatal single-dose nevirapineAIDS, 2003
- Mother-to-child HIV transmission in resource poor settingsAIDS, 2003
- Vaginal lavage with chlorhexidine during labour to reduce mother-to-child HIV transmission: clinical trial in Mombasa, KenyaAIDS, 2001
- Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trialThe Lancet, 1999